FRONTEO Inc.

09/17/2024 | Press release | Distributed by Public on 09/16/2024 19:47

AI drug discovery website revamped

2024.09.17News

- -

AI drug discovery website revamped

We have added a new description of our collaboration with Springer Nature and enhanced the content of our AI drug discovery support service that specializes in hypothesis generation.

FRONTEO, Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

FRONTEO is pleased to announce that it has relaunched its AI drug discovery website in September 2024.

We are developing innovative AI drug discovery support services that use our proprietary AI technology to discover unknown information from known information, predict unreported genes with high disease relevance, and provide target genes for drug discovery and the hypotheses that support them.

In this renewal, we have enhanced the content to enable visitors to gain a deeper understanding of our AI drug discovery support services, by adding pages that introduce new services based on collaboration with Springer Nature and our unique analysis methods in an easy-to-understand manner with illustrations.

website: https://lifescience.fronteo.com/products/drug-discovery-ai-factory/